Best of 2024: Efficacy of Biologics in Patients with Chronic Kidney Disease

Save

A retrospective cohort study of biological disease-modifying antirheumatic drugs (bDMARDs) persistence in rheumatoid arthritis patients with chronic kidney disease, shows the 3 year survival to be under 50% but that all studied biologics were nearly equivalents with regard to safety and efficacy.

Abuse of the Safety-Net 340B Drug Programs

Save

Dr. Madelaine Feldman has written an important commentary on the 340B Drug Pricing Program, a safety-net program that would allow vulnerable populations to receive expensive new therapies. But she points out that "this well-intentioned program has strayed from its original purpose", allowing certain hospitals and for-profit pharmacies to exploit the program.

Tocilizumab Efficacy in Giant Cell Arteritis Phenotypes

Save

Biosimilars Do Impact Biologic Drug Costs

Save

Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic drop in net spending for these products -- even though biosimilars barely dented Humira prescription rates.

ICYMI: Sex related differences in PsA

Save

Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA).

ICYMI: Are Emulation Trials a Fantasy?

Save

Are emulation ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized controlled trials (RCTs)?

ICYMI: GLP-1 Agonists Show Promise in Slowing Kidney Disease in Lupus Nephritis

Save

A retrospective cohort study presented at #ACR24 explores the benefits of GLP-1Ras in reducing the risk of end-stage renal disease (ESRD) for patients with lupus nephritis. Drawing on data from the TrinetX global research database, the study examines how GLP-1Ras may reduce ESRD progression in a population where 10-20% progress to ESRD within five years, even with immunosuppressive therapies.